{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+immune+globulin&page=2",
    "query": {
      "intervention": "intravenous immune globulin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 2175,
    "total_pages": 218,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+immune+globulin&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=intravenous+immune+globulin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T10:57:31.796Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01012323",
      "title": "A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases"
      ],
      "interventions": [
        {
          "name": "NewGam",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2010-01",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-16",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 7,
      "location_summary": "Irvine, California • Centennial, Colorado • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01012323"
    },
    {
      "nct_id": "NCT00569803",
      "title": "Subcutaneous Pharmacokinetics of Belatacept",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Transplantation"
      ],
      "interventions": [
        {
          "name": "belatacept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 153,
      "start_date": "2007-12",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-22",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00569803"
    },
    {
      "nct_id": "NCT00785941",
      "title": "A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "IMC-A12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2006-04",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2011-10-13",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00785941"
    },
    {
      "nct_id": "NCT02043379",
      "title": "Post-bypass Prophylactic IVIG in Infants and Neonates",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypogammaglobulinemia",
        "Congenital Heart Disease"
      ],
      "interventions": [
        {
          "name": "IVIG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "Up to 6 Months"
      },
      "enrollment_count": 50,
      "start_date": "2014-05",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-13",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02043379"
    },
    {
      "nct_id": "NCT05329766",
      "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Tract Malignancies"
      ],
      "interventions": [
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Quemliclustat",
          "type": "DRUG"
        },
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2022-06-10",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05329766"
    },
    {
      "nct_id": "NCT03746041",
      "title": "A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "abaloparatide",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2019-02-14",
      "completion_date": "2022-06-06",
      "has_results": false,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03746041"
    },
    {
      "nct_id": "NCT05525286",
      "title": "Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "SOT102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SOTIO Biotech a.s.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2022-03-31",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Cleveland, Ohio",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05525286"
    },
    {
      "nct_id": "NCT03463473",
      "title": "A Phase I Study of MSB2311 in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "3 mg/kg Q3W MSB2311 Injection",
          "type": "DRUG"
        },
        {
          "name": "10 mg/kg Q3W MSB2311 Injection",
          "type": "DRUG"
        },
        {
          "name": "20 mg/kg Q3W MSB2311 Injection",
          "type": "DRUG"
        },
        {
          "name": "10 mg/kg Q2W MSB2311 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Transcenta Therapeutics (Hangzhou) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2018-04-12",
      "completion_date": "2020-06-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-18",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03463473"
    },
    {
      "nct_id": "NCT00298272",
      "title": "Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "IDEC-C2B8 (rituximab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Folate",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2006-05",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 18,
      "location_summary": "Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00298272"
    },
    {
      "nct_id": "NCT02654639",
      "title": "Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "TAS-102",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-02",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-08T10:57:31.796Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654639"
    }
  ]
}